NGI and Affinity Proteomics seminar
March 10 @ 15:00 – 17:00 CET
Next-generation affinity proteomics – inspiration for analysis and validation at SciLifeLab
The proteome refers to the entire set of proteins produced by all genes in the body, and it is both dynamic and highly personalized. A protein biomarker indicates a change in expression or its state that correlates with the risk or progression of a disease, or with the susceptibility of a disease to a given treatment. Such unique biomarkers are often found in low concentrations in plasma. The Proximity Extension Assay (PEA) commercialized by Olink Proteomics is one of the technologies developed to quantify plasma biomarkers from a range of concentrations and offers a high-throughput alternative to traditional methods, such as ELISA.
The newly released Olink Explore technology brings together the specificity of PEA with a high throughput Next Generation Sequencing (NGS) readout, which today enables multiplex analysis of >3000 proteins from only a few microliters of body fluid. This technique is now available to researchers in Sweden via a collaboration between Affinity Proteomics and the National Genomics Infrastructure (NGI) at the SciLifeLab Explore Lab, physically located at BMC in Uppsala. During the seminar we will briefly present the Olink Explore technology and data from users to give guidance and inspiration for future projects.
The seminar will be recorded and can be found at the SciLifeLab YouTube channel about 2 days after the event.
The Zoom link will be provided in the confirmation email.
For more information, please contact firstname.lastname@example.org
|15:00||Welcome and introduction|
Mikael Åberg, Head, Affinity Proteomics Uppsala
Jessica Nordlund, Facility Director, NGI Uppsala (moderator)
|15:05||Olink Explore: Broader, faster and more comprehensive proteomics|
Nikolaos Tertipis, Olink Proteomics
|15:15||Strategies for validating biomarkers in biofluids |
Claudia Fredolini, Head, Affinity Proteomics Stockholm
|15:25||Experiences from a pilot study with Olink Explore in two ovarian cancer cohorts |
Stefan Enroth, associate professor, Uppsala University
|15:45||Multiplatform approach for plasma proteomics in health and disease |
Fredrik Edfors, Senior Researcher, Karolinska Institutet
|16:05||Disease-associated module enrichment and preanalytical considerations for robust biomarker discovery|
Sandra Hellberg, Postdoktor, Linköping University
& Ingrid Skelton Kockum, Professor, Karolinska Institutet
Jessica Nordlund and Mikael Åberg
|17:00||End of day|